Treatment Eligibility: We determine if you qualify for: Medical Weight Loss: Prescriptions for Semaglutide or Tirzepatide
GDMT for HFrEF typically includes evidence-based beta-blockers, angiotensin receptor neprilysin inhibitors (ARNIs), angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, mineralocorticoid receptor antagonists (MRA), and sodium-glucose cotransporter 2 inhibitors (SGLT2is), particularly in patients with obesity or T2DM [53]
Certain foods may stimulate natural GLP-1 release, including: High-protein foods such as eggs, fish, and legumes
Body weight and BMI play a role in determining eligibility for weight management trials, with most retatrutide studies enrolling adults with a BMI of 30 kg/m or above, or 27 kg/m or above in the presence of weight-related comorbidities such as hypertension or dyslipidaemia
The bottom line on this debate If you can access and afford brand-name GLP-1 medications through insurance, they are the safer choice from a regulatory standpoint
Many studies on the correlation between the function of GLP-1RAs and the development and progression of tumors are also underway
